search
Back to results

PCSK9 Inhibitor Treatment for Patients With SPG5

Primary Purpose

Hereditary Spastic Paraplegia Type 5

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
evolocumab
Sponsored by
First Affiliated Hospital of Fujian Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hereditary Spastic Paraplegia Type 5

Eligibility Criteria

14 Years - 80 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 14-80 years
  • Probands with clinically manifest hereditary spastic paraplegia
  • Genetically confirmed diagnosis of SPG5

Exclusion Criteria:

  • Comprised treatment with statins 3 months prior to enrolment
  • Contraindications to PCSK9 inhibitor therapy
  • Pregnancy was excluded in women of childbearing age

Sites / Locations

  • Department of Neurology , First Affiliated Hospital Fujian Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Evolocumab group

Arm Description

Eligible patients receive subcutaneous injections of evolocumab 420 mg

Outcomes

Primary Outcome Measures

The change of 27-hydroxycholesterol (27-OHC)
Cholesterol is initially side chain oxidized and the resulting 27-hydroxycholesterol (27-OHC) are 7a-hydroxylated

Secondary Outcome Measures

Full Information

First Posted
September 22, 2019
Last Updated
November 21, 2021
Sponsor
First Affiliated Hospital of Fujian Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT04101643
Brief Title
PCSK9 Inhibitor Treatment for Patients With SPG5
Official Title
PCSK9 Inhibitor Treatment for Patients With Hereditary Spastic Paraplegia Type 5
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
September 29, 2019 (Actual)
Primary Completion Date
January 3, 2023 (Anticipated)
Study Completion Date
January 3, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
First Affiliated Hospital of Fujian Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Spastic paraplegia type 5 (SPG5) is a rare subtype of hereditary spastic paraplegia, a highly heterogeneous group of neurodegenerative disorders defined by progressive neurodegeneration of the corticospinal tract motor neurons. SPG5 is caused by recessive mutations in the gene CYP7B1 encoding oxysterol-7a-hydroxylase. This enzyme is involved in the degradation of cholesterol into primary bile acids. CYP7B1 deficiency has been shown to lead to accumulation of neurotoxic oxysterols. Oxysterols were found to impair metabolic activity and viability of human cortical neurons at concentrations found in SPG5 patients, indicating that elevated levels of oxysterols might be key pathogenic factors in SPG5. Monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) have emerged as a new class of drugs that effectively lower cholesterol levels. Evolocumab, a member of this class, is a fully human monoclonal antibody that reduces LDL cholesterol levels by approximately 60%. We thus performed this interventional trial with Evolocumab 420 mg for SPG5 patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hereditary Spastic Paraplegia Type 5

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Evolocumab group
Arm Type
Experimental
Arm Description
Eligible patients receive subcutaneous injections of evolocumab 420 mg
Intervention Type
Drug
Intervention Name(s)
evolocumab
Intervention Description
Eligible patients receive subcutaneous injections of evolocumab 420 mg
Primary Outcome Measure Information:
Title
The change of 27-hydroxycholesterol (27-OHC)
Description
Cholesterol is initially side chain oxidized and the resulting 27-hydroxycholesterol (27-OHC) are 7a-hydroxylated
Time Frame
up to 4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 14-80 years Probands with clinically manifest hereditary spastic paraplegia Genetically confirmed diagnosis of SPG5 Exclusion Criteria: Comprised treatment with statins 3 months prior to enrolment Contraindications to PCSK9 inhibitor therapy Pregnancy was excluded in women of childbearing age
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ying Fu
Phone
13920263588
Email
fuying1995@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wan-Jin Chen
Organizational Affiliation
First Affiliated Hospital Fujian Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Neurology , First Affiliated Hospital Fujian Medical University
City
Fuzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ying Fu
Email
fuying1995@163.com
First Name & Middle Initial & Last Name & Degree
Wan-Jin Chen

12. IPD Sharing Statement

Learn more about this trial

PCSK9 Inhibitor Treatment for Patients With SPG5

We'll reach out to this number within 24 hrs